Blood transcript analysis and metastatic recurrent small bowel carcinoid management

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Modlin, Irvin M ^a   Drozdov, Ignat ^b   Bodei, Lisa ^c   Kidd, Mark ^d  

^a Wren Laboratories   (United States)

^b Bering Limited   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

68Gallium; Biomarker; Blood; Carcinoid; Chromogranin A; Gene marker; Neuroendocrine tumor; PCR; PET CT

Indexed keywords

CHROMOGRANIN A; GADOTERIC ACID; GALLIUM 68;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARCINOID SYNDROME; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GENETIC TRANSCRIPTION; HUMAN; IMAGE ANALYSIS; MALE; METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; SMALL BOWEL CARCINOID; TUMOR DIAGNOSIS; BLOOD; CARCINOID TUMOR; GENETICS; INTESTINAL NEOPLASMS; MIDDLE AGED; PATHOLOGY;

CARCINOID TUMOR; CHROMOGRANIN A; HUMANS; INTESTINAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; POLYMERASE CHAIN REACTION; POSITRON-EMISSION TOMOGRAPHY;

EID: 84906827234     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-564     Document Type: Article

References (26)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
2. Giandomenico V, Modlin IM, Ponte´n F, Nilsson M, Landegren U, Bergqvist J, Khan MS, Millar RP, La˚ngstro¨m B, Borlak J, Eriksson B, Nielsen B, Baltzer L, Waterton JC, Ahlstro¨m H, O¨berg K. Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology 2013, 28:28.
3. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011, 40:111-134. viii. doi:10.1016/j.ecl.2010.12.001.
4. Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 2013, 8:e63364.
5. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R, Kidd M. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Ann Surg Oncol 2009, 16:487-498.
6. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010, 252:850-856.
7. Elias D, Lefevre JH, Duvillard P, Goe´re´ D, Dromain C, Dumont F, Baudin E. Hepatic metastases from neuroendocrine tumors with a " thin slice" pathological examination: they are many more than you think. Ann Surg 2010, 251:307-310. doi:10.1097/SLA.0b013e3181bdf8cf.
8. Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 2012, 53:1207-1215. doi:10.2967/jnumed.111.101469. Epub 2012 Jul 10.
9. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008, 100:1282-1289. Epub 2008 Sep 9.
10. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011, 29:934-943.
11. Frilling A, Akerstrom G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer 2012, 19:R163-R185. doi:10.1530/ERC-12-0024. Print 2012 Oct.
12. Schreiter NF, Brenner W, Nogami M, Buchert R, Huppertz A, Pape UF, Prasad V, Hamm B, Maurer MH. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012, 39:72-82. doi:10.1007/s00259-011-1935-5. Epub 2011 Sep 17.
13. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010, 91:101-109. Epub 2009 Dec 9.
14. Bodei L, Kidd M, Modlin I, Paganelli G. Nuclear medicine in the diagnosis and therapy of neuroendocrine tumors. Nuclear Oncology 2014, Wolters Kluwer Health, Akotlun C, Goldsmith S.
15. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013, 168:185-193. doi:10.1530/EJE-12-0836. Print 2013 Feb.
16. De Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007, 21:33-41.
17. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Mu¨ller HH, Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008, 6:820-827. Epub 2008 Jun 10.
18. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999, 86:858-865.
19. Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M, Shibata D. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 2007, 14:780-785. Epub 2006 Dec 5.
20. Sondenaa K, Sen J, Heinle F, Fjetland L, Gudlaugsson E, Syversen U. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg 2004, 28:890-895.
21. Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A. Limitations of Chromogranin A in clinical practice. Biomarkers 2012, 17:186-191. doi:10.3109/1354750X.2012.654511. Epub 2012 Feb 6.
22. Zuetenhorst JM, Korse CM, Bonfrer JM, Peter E, Lamers CB, Taal BG. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clin Chem 2004, 50:1634-1639. Epub 2004 Jul 9.
23. Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Ann Clin Biochem 2007, 44:300-307.
24. Modlin I, Drozdov I, Alaimo D, Callahan S, Teixiera N, Bodei L, Kidd M. A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection. Endocr Relat Cancer 2014, 21:615-28.
25. Modlin I, Drozdov I, Kidd M. A multitranscript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. J Clin Oncol 2013, 31(Suppl):A4137.
26. Stokkel MP, Rietbergen DD, Korse CM, Taal BG. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Nucl Med Commun 2011, 32:731-737.